Schrödinger vs XtalPi (2026)
The two listed computational chemistry platforms, both founded by physicists, both now blending simulation with learned models. Schrodinger licenses its software broadly and has the largest published and independently benchmarked method literature in this category, with a molecule from the platform in late stage development. XtalPi closes the loop physically, pairing quantum calculations and generative design with large scale robotic synthesis so molecules are actually made and tested, and it has a platform derived candidate in humans. Both listings force useful disclosure, and the thing to read in each is the revenue mix, because a large services component means part of what looks like platform capability is people doing work. If you want tools your chemists run, Schrodinger. If you want designs made and tested without building the laboratory, XtalPi is selling that loop.
- The physics based simulation methods are published and independently benchmarked across a large peer reviewed literature, which is the strongest technical transparency position in this category.
- It is genuinely licensed software with the broadest coverage here, so a pharmaceutical organisation can run it in house rather than entering a partnership.
- Evidence exists at both platform and asset level, including a molecule originated on the platform reaching late stage development.
- It closes the loop physically, combining quantum calculations and generative models with large scale robotic synthesis so designs are made and tested rather than only proposed.
- A platform derived molecule is already in humans, which is the evidence class that matters most in this category.
- A stock exchange listing forces the most granular commercial disclosure of anything here, so the revenue mix between software and services is visible rather than described.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Schrödinger and XtalPi are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Schrödinger | XtalPi |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2015 |
| Headquarters | New York, NY | Shenzhen, China and Boston, MA |
| Website | schrodinger.com | en.xtalpi.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Schrödinger its top capability grade on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure. Set against XtalPi, Schrödinger grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards XtalPi its top capability grade on Commercial Transparency and Setting and Specialty Coverage. Set against Schrödinger, XtalPi grades higher on AI Centrality. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Schrödinger or XtalPi?
On the axes where the AI Health Index separates them, Schrödinger grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and Security Certifications and Trust Center, and XtalPi grades higher on AI Centrality. Schrödinger leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Schrödinger and XtalPi differ most?
The widest separation the AI Health Index records between Schrödinger and XtalPi is on Model and Technology Transparency, where Schrödinger grades A and XtalPi grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Schrödinger and XtalPi grade the same?
The AI Health Index grades Schrödinger and XtalPi the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Schrödinger and XtalPi not disclosed?
At the last review, at least one of Schrödinger and XtalPi published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both companies are listed and both are therefore more disclosed than private peers, but read the revenue mix carefully in each case: a substantial services component means part of what a buyer experiences as platform capability is delivered by people, and the two do not scale the same way. XtalPi names its components freely and never quantifies their performance publicly. Neither holds a located security attestation. The physics against machine learning framing should not be overdrawn, since both now combine simulation and learned models and the difference is one of emphasis and lineage rather than of kind.